Latest Boehringer Ingelheim Corporation Stories
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct.
Company to make OFEV available to IPF community within 10 days, along with comprehensive patient support resources RIDGEFIELD, Conn., Oct.
RIDGEFIELD, Conn., Oct.
- LUX-Lung 8 trial met its primary endpoint of improving progression-free survival in patients treated with afatinib versus erlotinib after failure of first-line, platinum-based chemotherapy, reducing
RIDGEFIELD, Conn., Sept. 26, 2014 /PRNewswire/ - Boehringer Ingelheim applauds the U.S.
Approval Marks New Inhaler Choice for tiotropium RIDGEFIELD, Conn., Sept. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S.
- Boehringer Ingelheim obtains exclusive global rights for development and commercialization of CureVac's investigational therapeutic cancer vaccine CV9202 INGELHEIM and TUBINGEN, Germany,
RIDGEFIELD, Conn., Sept.
- an ornament or knob in the shape of a flower